logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer: Late Stage Study Of Regorafenib Meets Primary Goal In Tumor Patients

Bayer AG's (BYR.L,BAYRY.PK,BAYZF.PK) Bayer HealthCare on Tuesday announced positive results from its Phase III trial GRID evaluating its investigational compound regorafenib for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors, or GIST, whose disease has progressed despite prior treatment with imatinib and sunitinib.

The trial met its primary endpoint of statistically significantly improving progression-free survival. The safety and tolerability of regorafenib were generally as expected in the study. Detailed data from the study are expected to be presented at an upcoming scientific meeting.

Kemal Malik, Head of Global Development and member of the Bayer HealthCare Executive Committee, said, "Additional treatment options are needed for GIST patients after failure of approved drugs. These findings may represent important progress in this difficult-to-treat disease with high unmet patient need."

Bayer plans to submit regorafenib for marketing authorization in the treatment of metastatic and/or unresectable GIST based on these data.

Regorafenib has also shown positive results in a Phase III trial for the treatment of patients with metastatic colorectal cancer whose disease has progressed after approved standard therapies. Bayer plans to submit regorafenib for marketing authorization in this indication in the first half of 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Warren Buffett's Berkshire Hathaway is reportedly planning its first ever European bond sale of 3 billion euros to take advantage of low interest rates in the region, traversing a path taken by a range of home companies in search of cheap funding options. The move comes as the European Central Bank's bond-buying stimulus program of 60 billion euros a month is imminent. Diary products company Prairie Farms is teaming up with Just Born, the maker of marshmallow candies PEEPS, to launch PEEPS flavored milk just in time for Easter. HKBN Ltd. has reportedly raised about $750 million after the broadband service provider priced its initial public offering at the top end of the price range. Private-equity group CVC Capital Partners, an unit of Carlyle Group L.P. (CG), Singapore's sovereign-wealth fund GIC Ltd., and other shareholders...
comments powered by Disqus
Follow RTT